Clin2
NCT06402955Worth exploringRecruiting

Imaging depression in Parkinson's disease

Parkinson's DiseaseMajor Depressive Disorder

Treatments studied

Part of Brain & nervous system, Mental health clinical trials.

This study uses brain imaging (PET scans) to understand depression in people with Parkinson's disease. It may also test a depression treatment called ketamine, but the main goal is to see how the brain changes with depression.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
120 people
Ages
40 years to 80 years
Study type
Interventional

Who can take part

  • You are between 40 and 80 years old.
  • You have been diagnosed with Parkinson's disease and are able to understand and agree to PET scans (a special brain imaging test).
  • You have moderate to severe depression symptoms (a score of 15 or more on a depression rating scale).
  • You do not have dementia, other major psychiatric disorders, or unstable medical conditions that would increase risk.
  • You are not taking certain medications that affect the brain imaging (like levetiracetam).
  • If you are a woman who could become pregnant, you must have a negative pregnancy test before the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06231563Recruiting· Phase 2
Ketamine for depression in veterans with Parkinson's

This study tests if ketamine can help treat depression in veterans with Parkinson's disease. It involves several in-person and remote visits, and you will need to avoid certain medications and cannabis for a short time before and during some visits.

San Francisco, California
NCT05516732Recruiting
Testing serotonin activity in the brain in people with Parkinson’s

This study uses special scans to measure how serotonin is released in parts of the brain involved in movement in Parkinson’s disease. It may help researchers understand disease changes and the role of serotonin systems in movement problems.

Exeter, Devon
NCT04396873Recruiting· Phase 1
PET brain scan study of inflammation markers in neurodegeneration

This Phase 1 study tests a PET scan to measure inflammation-related changes in the brain using a medication called ketoprofen. It may help researchers understand which people with certain brain diseases could benefit from treatments aimed at inflammation.

Bethesda, Maryland
NCT06303921Recruiting· Early Phase 1
Study of a new brain imaging agent for Parkinson's disease

This trial uses a special PET scan to see how a new imaging agent (called 11C-M503) travels through the body and brain. It may help researchers better understand brain conditions like Parkinson's disease.

New Haven, Connecticut
NCT07640555Recruiting· Early Phase 1
Brain imaging study for Parkinson's and related movement disorders

This research study tests a new type of brain scan (called a PET scan) that may help detect early signs of Parkinson's disease and similar conditions. You'll receive the scan and may have a spinal tap to check for specific protein markers.

New Haven, Connecticut
NCT03537794Recruiting
Brain scan study in depression using a dopamine binding marker

This study uses a special brain imaging scan (PET) to measure how dopamine receptors are binding in people with treatment-resistant depression, compared with healthy volunteers. It aims to better understand brain chemistry differences that may help guide future treatment.

Toronto, Ontario

Hear when a new Parkinson’s disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.